IPO Date: Dec 11 to Dec 13 2024
Listing Date: Dec 18 2024
1. Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company; and
2. General corporate purposes.
...
the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (“NCE”), to global pharmaceutical innovator companies and biotechnology firms. We possess both (a) discovery / contract research (“CRO”) and (b) chemistry, manufacturing, and control (“CMC”) / contract development and manufacturing organization (“CDMO”) capabilities. We are the fastest-growing Indian CRDMOs among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR from Financial Year 2022 to Financial Year 2024. (Source: F&S Report) Our CRDMO platform provides multiple entry points for us to acquire customers in the intermediate stages of their new drug discovery to commercialization journey. We are also one of the few CRDMOs to have a unique delivery model of having research laboratories for discovery and development located near overseas innovation hubs at Watertown (Greater Boston, MA), United States (“US”) and Manchester, United Kingdom (“UK”), complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India. (Source: F&S Report) During the Financial Year 2024, we served more than 280 innovator pharmaceutical companies, including 18 of the top 25 pharmaceutical companies (in terms of revenue for the calendar year 2023), across regulated markets, including the US, the UK, Europe and Japan. (Source: F&S Report) During the Financial Year 2024, we also provided CRO services to more than 60 customers on an ongoing basis, for their integrated drug discovery programs. As of March 31, 2024, our CDMO product portfolio included more than 150 innovator pharmaceutical products, including 38 products that were supplied for manufacturing of 28 commercial drugs. Read MoreK FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Posted on Dec 23rd
Real Touch Finance informs about closure of trading window
Posted on Dec 23rd
Conspiracy to defame India's institution': BJP's Tarun Chugh slams Rahul Gandhi over his remarks in Germany
Posted on Dec 23rd
Currency futures for December expiry trade weaker with 1.23% decrease in OI
Posted on Dec 22nd
Nanta Tech coming with IPO to raise Rs 31.81 crore
The issue size of Sai Life Sciences Ltd. IPO is ₹2026.92 - 2131.76 crore.
The Sai Life Sciences Ltd. IPO opens for subscription on 2024-12-11 and closes on 2024-12-13.
The price range of Sai Life Sciences Ltd. IPO is ₹522.00 to ₹549.00.
The lot size of Sai Life Sciences Ltd. IPO is 27 shares.
The registrar of Sai Life Sciences Ltd. IPO is K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.).
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.